'The second quarter delivered strong momentum for
'Moving forward over the next few quarters, we expect to see topline results for the Phase 3 study in dry eye disease in the US, while enhancing our portfolio through open collaborations. HanAll will continue to invest in R&D to bring innovative therapeutics to patients' he added.
SECOND QUARTER 2022 BUSINESS UPDATE
Pipeline Development Highlights
A comprehensive update on HanAll's pipeline development includes an overview of HanAll's research and a list of compounds in development with targeted indication and the phase of development.
Batoclimab (Project Code: HL161)
A novel, fully human, anti-FcRn antibody being developed as a subcutaneous injection for the treatment of rare autoimmune diseases mediated by pathogenic IgG antibodies degree In
Tanfanercept (Project Code: HL036)
A novel, topical anti-TNF alpha biologic therapy for dry eye disease (DED) which aims to treat inflammatory eye diseases by inhibiting TNF alpha, which is critical in ocular inflammation. degree?HanAll Biopharma and
HL187/ HL186
HanAll is advancing its development in immuno-oncology therapeutics, that respectively target TIM-3 and TIGIT with
Major Development Highlights
HanAll further advanced its partnerships with companies with promising technologies. degree??HanAll supported Neudive, a company developing digital therapeutic solutions to help neurodiverse children. Neudive's platform is expected to deliver individually tailored therapy programs to children with neurodevelopmental disorders by using VR technology
About
HanAll has also expanded its focus to ophthalmology, immunology, oncology and neurology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. A leading pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody drug, is in Phase 3 and Phase 2 trials across the world for the treatment of rare autoimmune disorders including myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, and immune thrombocytopenia. Another main asset, HL036 (INN: tanfanercept), an anti-TNF alpha protein drug, is in Phase 3 clinical trials in the US and
Contact:
Media
HanAll PR/IR
E: pr@hanall.com
E: ir@hanall.com
Disclaimer statement
The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements.' These forward-looking statements can be identified by the use of forward-looking terminology, including the terms 'believes,' 'estimates,' 'anticipates,' 'expects,' 'intends,' 'may,' 'will,' or 'should' and include statements HANALL (the company, we) makes concerning its 2022 business and financial outlook and related plans, the therapeutic potential of its product candidates, the intended results of its strategy and the company, and its collaboration partners', advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts, the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors our expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements, our reliance on collaborations with third parties, estimating the commercial potential of our product candidates, our ability to obtain and maintain protection of intellectual property for its technologies and drugs, our limited operating history, and our ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in
Contact:
Customer Center
T: +82 1644-5515
Sales Opportunity/Product
E: sales.info@hanall.co.kr
Investor
E: ir@hanall.com
Media
E: pr@hanall.com
(C) 2022 Electronic News Publishing, source